

EOSINOPHILIC MUCUS CHRONIC RHINOSINUSITIS: AN IMMUNOLOGICAL PERSPECTIVE

Harshita Pant MBBS

Department of Surgery

Faculty of Health Sciences

Adelaide University

South Australia

2005

A thesis submitted in fulfilment of the requirements for the Degree of Doctor of Philosophy

TABLE OF CONTENTS

Precis		1
Declara	ation	iii
Ackno	wledgements	iv
Publica	Publications	
Present	tations	vii
Ethics		ix
List of	figures	x
List of	tables	xiii
Abbrev	viations	xiv
СНА	PTER ONE: LITERATURE REVIEW	
1.1	INTRODUCTION	1
1.2	PARANASAL SINUSES	3
1.3	CHRONIC RHINOSINUSITIS	4
1.4	PATHOGENESIS OF CHRONIC RHINOSINUSITIS	5
1.5	SINONASAL POLYPS	9
1.6	ALLERGIC FUNGAL SINUSITIS OR ALLERGY, FUNGI AND	
	SINUSITIS?	11
1.6.1	Historical background	11
1.6.2	Eosinophilic mucus	14
1.6.3	Diagnostic criteria for allergic fungal sinusitis	15
1.7	CLINICAL CHARACTERISTICS OF ALLERGIC FUNGAL	
	SINUSITIS	16
1.7.1	Demographics	16
1.7.2	Clinical profile	16
1.7.3	Treatment and prognosis	18

1.8	ALLERGIC FUNGAL SINUSITIS AND ALLERGIC BRONCHO- PULMONARY ASPERGILLOSIS: STRIKING SIMILARITIES AND	
	OBVIOUS DIFFERENCES	19
1.9	EOSINOPHILIC MUCUS CHRONIC RHINOSINUSITIS	21
1.10	ROLE OF FUNGI IN THE MUCOSAL INFLAMMATION IN	
	EOSINOPHILIC MUCUS CHRONIC RHINOSINUSITIS	22
1.10.1	Fungal allergy	23
1.10.2	Invasive and toxic fungal disease	24
1.11	THE APPROACH TO EXAMINING THE MUCOSAL	
	INFLAMMATION IN CHRONIC RHINOSINUSITIS	26
1.12	SINONASAL MUCOSAL IMMUNE SYSTEM	26
1.12.1	Physicochemical barrier	27
1.12.2	Lymphoid compartments	29
1.13	CHARACTERISATION OF THE MUCOSAL IMMUNE CELLS	29
1.14	MUCOSAL IMMUNE RESPONSES	31
1.15	MUCOSAL INFLAMMATION IN CHRONIC RHINOSINUSITIS	35
1.16	ANALYSIS OF T LYMPHOCYTE FUNCTION	38
1.17	MOLECULAR MARKERS FOR T LYMPHOCYTE MEMORY,	
	MIGRATION AND DIFFERENTIATION	40
1.17.1	Memory	40
1.17.2	Migration	40
1.17.3	Differentiation	41
1.18	PHENOTYPIC IDENTIFICATION OF NAÏVE AND MEMORY T	
	LYMPHOCYTE POPULATIONS	42
1.18.1	Naïve T lymphocytes	42
1.18.2	Central memory and effector memory T lymphocytes	42
1.19	EFFECTOR FUNCTIONS OF T LYMPHOCYTES	44
1.19.1	Perforin and granulysin	44
1.19.2	Granzymes	46
1.20	RESEARCH PLAN	47

CHAPTER TWO: MATERIALS AND METHODS

2.1	ANTIBODIES	49
2.1.1	Antibodies for ELISA experiments	49
2.1.2	Antibodies for flow cytometry experiments	50
2.1.3	Antibodies for immunohistochemistry experiments	51
2.2	GENERAL	53
2.3	FUNGAL ANTIGENS	53
2.4	PATIENTS AND CONTROLS	53
2.4.1	Recruitment of patients and healthy volunteers	53
2.4.2	Selection of study groups	54
2.4.2.1	Eosinophilic mucus chronic rhinosinusitis (EMCRS) patients	54
2.4.2.2	Chronic rhinosinusitis (CRS) patients	54
2.4.2.3	Allergic rhinitis with fungal allergy (ARFA) patients	55
2.4.2.4	Healthy volunteers (HV)	55
2.4.3	Study groups in the result chapters	55
2.4.4	Exclusion criteria	55
2.5	COLLECTION OF BIOLOGICAL SPECIMENS	56
2.5.1	Peripheral venous blood samples	56
2.5.2	Sinonasal samples	56
2.5.2.1	Tissue	56
2.5.2.2	Mucus	57
2.6	ROUTINE DIAGNOSTIC TESTS	57
2.6.1	Sinonasal samples	57
2.6.1.1	Polyp and non-polyp mucosal tissue	57
2.6.1.2	Sinonasal mucus histology	58
2.6.1.3	Sinonasal mucus mycology	58
2.6.2	Radiology	58
2.6.3	Peripheral blood allergen-specific IgE	59
2.6.4	Skin prick tests	59
2.6.5	Peripheral blood total immunoglobulin levels, differential leucocyte	
	counts and Aspergillus fumigatus precipitin levels	59

2.7	DEMOGRAPHICS	60
2.8	SYMPTOM SCORES	60
2.8.1	Chronic rhinosinusitis	60
2.8.2	Asthma	61
2.9	ENZYME-LINKED IMMUNOSORBENT ASSAY	63
2.9.1	General ELISA method	63
2.9.2	Measurement of antibody concentration in culture supernatants	63
2.10	DEVELOPMENT OF THE FUNGAL ANTIBODY ELISA	64
2.10.1	Optimisation of the coating fungal antigen concentration	65
2.10.2	Optimisation of primary antibody dilution for each fungal-specific	
	antibody isotype	65
2.10.3	Optimisation of secondary antibody concentration	65
2.11	ESTABLISHMENT OF THE FUNGAL ANTIGEN-SPECIFIC	
	IMMUNOGLOBULIN E ELISA	66
2.11.1	Sensitivity and specificity of the IgE ELISA	66
2.12	BRADFORD ASSAY	67
2.13	CELL CULTURE MEDIA AND CULTURE CONDITIONS	68
2.14	CELL PROLIFERATION	68
2.14.1	Preparation of mononuclear cells from peripheral blood and nasal polyps	68
2.14.2	Labelling peripheral blood mononuclear cells with 5-(6)-	
	carboxyfluorescein succinimidyl ester (CFSE)	69
2.14.3	Assessment of cell proliferation using tritiated thymidine incorporation	
	method	69
2.14.4	Assessment of cell division using CFSE-cytometry	70
2.15	ESTABLISHMENT OF THE FUNGAL-SPECIFIC MONONUCLEAR	
	CELL PROLIFERATION ASSAY	73
2.16	FUNGAL-SPECIFIC MONONUCLEAR CELL PROLIFERATION IN	
	THE STUDY GROUPS	75
2.17	MONOCLONAL ANTIBODY PRODUCTION, PURIFICATION AND	
	CONJUGATION	75
2.17.1	Monoclonal antibody production from hybridomas	75

2.17.2	Antibody purification	76
2.17.3	Fluorescein labelling of proteins	76
2.18	PREPARATION OF SINONASAL TISSUE FOR THE	
	EXPERIMENTAL PROCEDURES	77
2.18.1	Preparation of single cell suspensions	77
2.18.2	Preparation of paraffin blocks	78
2.19	CYTOSPIN PREPARATIONS OF NASAL POLYP TISSUE	78
2.20	IMMUNOFLUORESCENCE STAINING FOR FLOW CYTOMETRY	78
2.20.1	Detection of cell surface membrane molecules	79
2.20.2	Detection of intracellular molecules	80
2.21	FLOW CYTOMETRIC ANALYSIS	80
2.22	IMMUNOHISTOCHEMICAL LOCALISATION OF THE	
	INFLAMMATORY CELLS IN NASAL POLYPS	81
2.23	DATA ANALYSIS	83
CHAI	PTER THREE: DEMOGRAPHIC, CLINICAL AND	
	PTER THREE: DEMOGRAPHIC, CLINICAL AND UNOLOGICAL FEATURES OF EMCRS PATIENTS	
		84
IMM	UNOLOGICAL FEATURES OF EMCRS PATIENTS	84 85
IMM) 3.1	UNOLOGICAL FEATURES OF EMCRS PATIENTS INTRODUCTION	
3.1 3.2	UNOLOGICAL FEATURES OF EMCRS PATIENTS INTRODUCTION RESULTS	85
3.1 3.2 3.2.1	INTRODUCTION RESULTS Demographics	85 85
3.1 3.2 3.2.1 3.2.2	INTRODUCTION RESULTS Demographics Clinical history, symptoms and signs	85 85 90
3.1 3.2 3.2.1 3.2.2 3.2.3	INTRODUCTION RESULTS Demographics Clinical history, symptoms and signs Sinus computed tomography findings	85 85 90 93
3.1 3.2 3.2.1 3.2.2 3.2.3 3.2.4	INTRODUCTION RESULTS Demographics Clinical history, symptoms and signs Sinus computed tomography findings Sinus mucus and polyp histology	85 85 90 93
3.1 3.2 3.2.1 3.2.2 3.2.3 3.2.4 3.2.5	INTRODUCTION RESULTS Demographics Clinical history, symptoms and signs Sinus computed tomography findings Sinus mucus and polyp histology Mucus mycology	85 85 90 93
3.1 3.2 3.2.1 3.2.2 3.2.3 3.2.4 3.2.5	INTRODUCTION RESULTS Demographics Clinical history, symptoms and signs Sinus computed tomography findings Sinus mucus and polyp histology Mucus mycology Peripheral blood total immunoglobulin levels, differential leucocyte	85 85 90 93 93
3.1 3.2 3.2.1 3.2.2 3.2.3 3.2.4 3.2.5 3.2.6	INTRODUCTION RESULTS Demographics Clinical history, symptoms and signs Sinus computed tomography findings Sinus mucus and polyp histology Mucus mycology Peripheral blood total immunoglobulin levels, differential leucocyte counts and Aspergillus fumigatus precipitin levels	85 85 90 93 93 97

CHAPTER FOUR: FUNGAL-SPECIFIC HUMORAL RESPONSE IN EMCRS PATIENTS

4.1	INTRODUCTION	108
4.2	RESULTS	109
4.2.1	Validation of the fungal antibody ELISA	109
4.2.2	Profile of Alternaria alternata and Aspergillus fumigatus-specific	
	antibodies in sera of EMCRS patients	113
4.2.2.1	Total and fungal-specific IgE	113
4.2.2.2	Fungal-specific IgG, IgA and IgM	116
4.2.2.3	Fungal-specific IgG subclasses	117
4.2.2.4	Relationship between fungal-specific immunoglobulin levels and the	
	detection of fungus in eosinophilic mucus	118
4.3	DISCUSSION	120
V	PTER FIVE: FUNGAL-SPECIFIC PERIPHERAL OD T LYMPHOCYTE PROLIFERATION IN EMCRS ENTS	
5.1	INTRODUCTION	123
5.2	RESULTS	125
5.2.1	Establishment of the fungal-specific cell proliferation assay	125
5.2.2	Magnitude of fungal-specific mononuclear cell proliferation	128
5.2.2.1	Peripheral blood	128
5.2.2.2	Nasal polyp	131
5.2.3	Phenotype of the fungal-specific mononuclear cells	133
	Thenotype of the languar-specific monoracieal cens	155

CHAPTER SIX: CHARACTERISATION OF
LYMPHOCYTE POPULATIONS IN SINONASAL POLYPS

6.1	INTRODUCTION	145
6.2	RESULTS	147
6.2.1	Immunohistochemical localisation of the inflammatory cells in nasal	
	polyps	147
6.2.2	Flow cytometry - direct and indirect immunofluorescence	150
6.2.2.1	Cellular profile of nasal polyps from EMCRS and CRS patients	150
6.2.2.2	Lymphocyte populations in polyps and peripheral blood of EMCRS and	
	CRS patients	151
6.2.3	CD4 ⁺ and CD8 ⁺ T lymphocyte populations in polyps and peripheral	
	blood	153
6.2.4	Phenotype of T lymphocytes with respect to their expression of	
	CD45RA, CD62L and CD27 molecules	156
6.2.5	Cytotoxic phenotype of the T lymphocytes	161
6.2.6	MHC II and CD25 expression on T lymphocytes	164
6.2.7	Evidence for T lymphocyte degranulation	166
6.3	DISCUSSION	168
CHA	PTER SEVEN: GENERAL DISCUSSION AND	
CON	CLUDING REMARKS	176
REFE	CRENCES	187
APPE	ENDIX	225
PUBI	LICATIONS	

PRÉCIS

Immunoglobulin E (IgE) – mediated systemic fungal allergy and fungi in sinus eosinophilic mucus are considered pathologically important in patients with eosinophilic mucus chronic rhinosinusitis (EMCRS). They are used to subgroup these patients into the following: allergic fungal sinusitis (AFS), AFS-like, non-allergic fungal eosinophilic sinusitis (NAFES) and non-allergic, non-fungal eosinophilic sinusitis (NANFES). The relevance of this classification system was examined in this thesis according to the clinical characteristics, systemic immune responses and the sinonasal lymphocyte populations in EMCRS patients. In doing so, it was established that the EMCRS subgroups were not significantly different from one another. However, as a single group, EMCRS patients had a more severe form of sinus disease than patients with chronic rhinosinusitis without eosinophilic mucus (CRS).

The total IgE and fungal-specific IgE-mediated allergic parameters were not significantly different between allergic EMCRS patients and disease-control group, allergic rhinitis with fungal allergy (ARFA). This indicated that fungal allergy was not of central pathogenic importance in EMCRS. Regardless of fungal allergy or of the detection of fungi, EMCRS patients had an elevated humoral and cellular immune response to *Alternaria alternata* and *Aspergillus fumigatus* compared with healthy volunteers. EMCRS patients were distinguished from ARFA and CRS groups by elevated fungal-specific serum IgG3 levels. Fungal-specific peripheral blood mononuclear cell proliferation was also increased in EMCRS patients. While CD4⁺ and CD8⁺ T lymphocytes proliferated in a proportion of ARFA and CRS patients, CD8⁺ T lymphocytes did not proliferate in EMCRS. This implied a dysregulated CD8⁺ T cell response to fungi. Compared with CRS, polyps from EMCRS patients had a greater proportion of effector memory CD8⁺ T lymphocytes lacking the cytotoxic phenotype defined by intracellular perforin. These findings indicated that

immunological mechanisms other than IgE-mediated fungal allergy were involved in EMCRS. These mechanisms were characterised by terminally differentiated and antigenexperienced CD8⁺ T lymphocytes in the mucosa.

The work presented here showed that eosinophilic mucus represented a distinct clinicopathological subset of chronic rhinosinusitis patients. The clinical subgrouping of EMCRS
was unfounded as IgE-mediated allergy was not the principal pathogenic mechanism, and all
the EMCRS subgroups had an elevated fungal-specific immune response. Although the
nature of the fungal involvement and disease mechanisms remain to be determined, this
thesis represents a major conceptual advance to determine the pathogenic processes in
eosinophilic mucus chronic rhinosinusitis.